Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine… Read more
Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has an Asset Resilience Ratio of 24.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Jiangsu Nhwa Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.18 Billion | 24.04% |
| Total Liquid Assets | CN¥2.18 Billion | 24.04% |
Asset Resilience Insights
- Good Liquidity Position: Jiangsu Nhwa Pharmaceutical Co Ltd maintains a healthy 24.04% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Nhwa Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Nhwa Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Jiangsu Nhwa Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Jiangsu Nhwa Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.12% | CN¥2.37 Billion | CN¥8.44 Billion | +9.90pp |
| 2023-12-31 | 18.22% | CN¥1.33 Billion | CN¥7.33 Billion | -4.18pp |
| 2022-12-31 | 22.40% | CN¥1.45 Billion | CN¥6.48 Billion | +3.82pp |
| 2021-12-31 | 18.58% | CN¥1.06 Billion | CN¥5.70 Billion | +0.95pp |
| 2020-12-31 | 17.63% | CN¥837.00 Million | CN¥4.75 Billion | +15.96pp |
| 2019-12-31 | 1.67% | CN¥70.00 Million | CN¥4.20 Billion | -10.86pp |
| 2018-12-31 | 12.53% | CN¥505.00 Million | CN¥4.03 Billion | +2.35pp |
| 2017-12-31 | 10.18% | CN¥336.05 Million | CN¥3.30 Billion | +6.14pp |
| 2016-12-31 | 4.03% | CN¥120.00 Million | CN¥2.97 Billion | -- |